FTY720, an immunomodulatory sphingolipid mimetic: Translation of a novel mechanism into clinical benefit in multiple sclerosis

Expert Opinion on Investigational Drugs

Volumn 16, Issue 3, 2007, Pages 283-289

  Baumruker, Thomas ^a   Billich, Andreas ^a   Brinkmann, Volker ^b  

^a Novartis Institutes for BioMedical Research Vienna   (Austria)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Endothelial barrier; FTY720; Lymphocytes; Multiple sclerosis; Sphingolipids

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; METHYLPREDNISOLONE; NITRIC OXIDE SYNTHASE; PLACEBO; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR;

ADAPTIVE IMMUNITY; ALLERGIC ENCEPHALOMYELITIS; ATHEROSCLEROSIS; BLOOD BRAIN BARRIER; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG BINDING; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG TARGETING; HEART PROTECTION; HEART RATE; HUMAN; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; MEAN ARTERIAL PRESSURE; MULTIPLE SCLEROSIS; NONHUMAN; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; VASODILATATION; VIRUS INFECTION;

ANIMALS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, LYMPHATIC; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTES; LYSOPHOSPHOLIPIDS; MULTIPLE SCLEROSIS; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOLIPIDS; SPHINGOSINE;

EID: 33947168769     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.3.283     Document Type: Review

References (53)

1. ADACHI K, KOHARA T, NAKAO N, ARITA M, CHIBA K, MISHINA Z: Design, synthesis and structure-activity relationships of 2-substituted 2-amino-1,3-propandiols: discovery of a novel immunosuppressant, FTY720. Bioorg. Med. Chem. Lett. (1995) 5:853-856.
2. CHEN JK, LANE WS, SCHREIBER SL: The identification of myriocin-binding proteins. Chem. Biol. (1999) 6:221-235.
3. CHIBA K, YANAGAWA Y, MASUBUCHI Y et al.: FTY720, a novel inummosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. (1998) 160:5037-5044.
4. WATTENBERG BW, PITSON SM, RABEN DM: The sphingosine and diacylglycerol kinase superfamily of signaling kinases: localization as a key to signaling function. J. Lipid Res. (2006) 47:1128-1139.
5. SCHWAB SR, PEREIRA JP, MATLOUBIAN M, XU Y, HUANG Y, CYSTER JG: Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science (2005) 309:1735-1739.
6. SPIEGEL S, CUVILLIER O, EDSALL LC et al.: Sphingosine-1-phosphate in cell growth and cell death. Ann. NY Acad. Sci. (1998) 845:11-18.
7. SPIEGEL S, MILSTIEN S: Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol. (2003) 4:397-407.
8. 1 acts within endothelial cells to regulate vascular maturation. Blood (2003) 102:3665-3667.
9. MIZUGISHI K, YAMASHITA T, OLIVERA A, MILLER GF, SPIEGEL S, PROIA RL: Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol. (2005) 25:11113-11121.
10. HLA T: Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. (2004) 15:513-520.
11. PYNE S, PYNE NJ: Sphingosine 1-phosphate signalling and termination at lipid phosphate receptors. Biochim. Biophys. Acta (2002) 1582:121-131.
12. BAUMRUKER T, BORNANCIN F, BILLICH A: The role of sphingosine and ceramide kinases in inflammatory responses. Immunol. Lett. (2005) 96:175-185.
13. GOETZL EJ, WANG W, MCGIFFERT C, HUANG MC, GRALER MH: Sphingosine 1-phosphate and its G protein-coupled receptors constitute a multifunctional immunoregulatory system. J. Cell Biochem. (2004) 92:1104-1114.
14. 3 lysophospholipid receptor. Circulation (2006) 114:1403-1409.
15. BRINKMANN V, DAVIS MD, HEISE CE et al: The immune modulator FTY720 targets sphingosine 1-phosphare receptors. J. Biol. Chem. (2002) 277:21453-21457.
16. MANDALA S, HAJDU R, BERGSTROM J et al: Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science (2002) 296:346-349.
17. BILLICH A, BORNANCIN F, DEVAY P, MECHTCHERIAKOVA D, URTZ N, BAUMRUKER T. Phosphorylation of the imunomodulatory drug FTY720 by sphingosine kinases. J Biol. Chem. (2003) 278:47408-47415.
18. ZEMANN B, KINZEL B, MULLER M et al.: Sphingosine kinase type 2 is essential for lymphopenia induced by the i inunomodulatory drug FTY720. Blood (2006) 107:1454-1458.
19. CHUN J, ROSEN H: Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr. Pharm. Des. (2006) 12:161-171.
20. GRAELER M, GOETZL EJ: Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEBJ (2002) 16:1874-1878.
21. MATLOUBIAN M, LO CG, CINAMON G et al: Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature (2004) 427:355-360.
22. BRINKMANN V, CYSTER JG, HLA T: FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. (2004) 4:1019-1025.
23. SINGER II, TIAN M, WICKHAM LA et al.: Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J. Immunol (2005) 175:7151-7161.
24. MCVERRY BJ, GARCIA JG: In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal. (2005) 17:131-139.
25. BRINKMANN V. BAUMRUKER T: Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr. Opin. Pharmacol (2006) 6:244-250.
26. SHIOW LR, ROSEN DB, BRDICKOVA N et al.: CD69 acts downstream ofinterferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature (2006) 440:540-544.
27. ROSEN H, GOETZL EJ: Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. (2005) 5:560-570.
28. PENG X, HASSOUN PM, SAMMANI S et al.: Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. (2004) 169:1245-1251.
29. SANCHEZ T, ESTRADA-HERNANDEZ T, PAIK JH et al.: Phosphorylarion and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. (2003) 278:47281-47290.
30. SANNA MG, WANG SK, GONZALEZ-CABRERA PJ et al.: Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. (2006) 2:434-441.
31. SINGLETON PA, DUDEK SM, MA SF, GARCIA JG: Transactivation of sphingosine-1-phosphate receptors is essential for vascular barrier regulation: novel role for hyaluronan and CD44 receptor family. J. Biol. Chem. (2006) 281(45):34381-34393.
32. COLOMBAIONI L, GARCIA-GIL M: Sphingolipid metabolites in neural signalling and function. Brain Res. Brain Res. Rev. (2004) 46:328-355.
33. 5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. (2005) 25:1459-1469.
34. MENO-TETANG GM, LI H, MIS S et al.: Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2 [2- (-4-octylphenyl) ethyl] propane-1,3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab. Dispos. (2006) 34:1480-1487.
35. FUJINO M, FUNESHIMA N, KITAZAWA Y et al.: Amelioration of experimental autommume encephalomyelitis in Lewis rats by FTY720 treatment. J. Pbarmacol. Exp. Ther. (2003) 305:70-77.
36. WEBB M, THAM CS, LIN FF et al.: Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. (2004) 153:108-121.
37. KATAOKA H, SUGAHARA K, SHIMANO K et al.: FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition ofT cell infiltration. Cell. Mol. Immunol. (2005) 2:439-448.
38. RAUSCH M, HIESTAND P, FOSTER CA, BAUMANN DR, CANNET C, RUDIN M: Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging (2004) 20:16-24.
39. KAPPOS L, ANTEL J, COMI G et al.: Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med (2006) 355:1124-1140.
40. MASSBERG S, VON ANDRIAN UH: Fingolimod and sphingosine-1-phosphate-modifiers of lymphocyte migration. N. Engl. J. Med. (2006) 355:1088-1091.
41. KOYRAKH L, LUJAN R, COLON J et al.: Molecular and cellular diversity of neuronal G-protein-gated potassium channels. J. Neurosci. (2005) 25:11468-11478.
42. 3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. (2004) 279:13839-13848.
43. FORREST M, SUN SY, HAJDU R et al.: Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J. Pharmacol. Exp. Ther. (2004) 309:758-768.
44. GUO J, MACDONELL KL, GILES WR: Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. (1999) 438:642-648.
45. + current in guinea-pig atrial myocytes by sphingosine-1-phosphate. J. Physiol. (1995) 489:701-707.
46. JAN LY, JAN YN: Heartfelt crosstalk: desensitization of the GIRK current. Nat. Cell Biol. (2000) 2:E165-E167.
47. 3- Circ. Res. (2005) 96:913-920.
48. KIMURA T, SATO K, MALCHINKHUU E et al: High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler. Thromb. Vasc. Biol. (2003) 23:1283-1288.
49. HWANG MW, MATSUMORI A, FURUKAWA Y et al: FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation (1999) 100:1322-1329.
50. PINSCHEWER DD, OCHSENBEIN AF, ODERMATT B, BRINKMANN V, HENGARTNER H, ZINKERNAGEL RM: FTY720 inummosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. (2000) 164:5761-5770.
51. MASOPUST D, LEFRANCOIS L: CD8 T-cell memory: the other half of the story. Microbes Infect. (2003) 5:221-226.
52. BRINKMANN V, CHEN S, FENG L, PINSCHEWER D, NIKOLOVA Z, HOF R: FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. Transplant. Proc. (2001) 33:530-531.
53. BRINKMANN V, PINSCHEWER D, CHIBA K, FENG L: FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. (2000) 21:49-52.